Wang Yudi, Feng Weiying, Wang Fudi, Min Junxia
Department of Hematology, Shaoxing People's Hospital, Shaoxing 312000, Zhejiang Province, China.
Institute of Translational Medicine, Zhejiang University, Hangzhou 310058, China.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024 Dec 25;53(6):735-746. doi: 10.3724/zdxbyxb-2024-0211.
It is reported that iron metabolism and ferroptosis can influence the occurrence and development of myeloid tumors, which can serve as therapeutic targets. Dysregulation of iron metabolism is present in a variety of myeloid neoplasms. The prognosis of acute myeloid leukemia is related to differential expression of molecules related to iron metabolism. The prognosis of myelodysplastic syndrome patients with iron overload is poor. Myeloproliferative neoplasms are often characterized by the coexistence of iron deficiency and erythrocytosis, which can be treated by targeting hepcidin. Myeloid tumor cells are susceptible to oxidative damage caused by the accumulation of reactive oxygen species and are sensitive to ferroptosis. Ferroptosis has anti-tumor effect in acute myeloid leukemia and myelodysplastic syndrome. Targeting ferroptosis can reverse imatinib resistance in chronic myeloid leukemia. This article reviews the characteristics of iron metabolism in the development and progression of myeloid neoplasms, as well as the mechanism of ferroptosis, to provide a basis for the development of new therapeutic strategies.
据报道，铁代谢和铁死亡可影响髓系肿瘤的发生发展，二者均可作为治疗靶点。铁代谢失调存在于多种髓系肿瘤中。急性髓系白血病的预后与铁代谢相关分子的差异表达有关。铁过载的骨髓增生异常综合征患者预后较差。骨髓增殖性肿瘤常表现为缺铁和红细胞增多并存，可通过靶向铁调素来治疗。髓系肿瘤细胞易受活性氧积累引起的氧化损伤，且对铁死亡敏感。铁死亡在急性髓系白血病和骨髓增生异常综合征中具有抗肿瘤作用。靶向铁死亡可逆转慢性髓系白血病对伊马替尼的耐药性。本文综述了髓系肿瘤发生发展过程中铁代谢的特点以及铁死亡的机制，为开发新的治疗策略提供依据。
